Biopharmaceutical aspects of gastro-retentive dosage forms: The gabapentin paradigm

Journal of Drug Delivery Science and Technology

Volumn 19, Issue 4, 2009, Pages 233-239

  Kagan, L ^a   Hoffman, A ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Bioavailability; Controlled release; Drug delivery system; Gabapentin; Gastro retentive dosage form; Intestinal absorption; Narrow absorption window; Pharmacokinetics; Saturable absorption

Indexed keywords

ATENOLOL; GABAPENTIN; GUAIFENESIN; RIBOFLAVIN;

AMYOTROPHIC LATERAL SCLEROSIS; CONTROLLED DRUG RELEASE; DIABETIC NEUROPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG RETENTION; EXPERIMENTAL MODEL; FOCAL EPILEPSY; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL MOTILITY; HOT FLUSH; HUMAN; INTESTINE ABSORPTION; MATHEMATICAL MODEL; NONHUMAN; POSTHERPETIC NEURALGIA; REVIEW; UPPER GASTROINTESTINAL TRACT;

EID: 69249084977     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(09)50046-9     Document Type: Review

References (46)

1. Amidon G.L., Lennernas H., Shah V.P., Crison J.R.-A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. - Pharm Res., 12, 413-420, 1995.
2. Buxton I.L.O. - Pharmacokinetics and pharmacodynaimics: the dynamics of drug absorption, distribution, action, and elimination. - In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, L.L. Brunton Ed., McGraw-Hill, New York, 2006.
3. Davis S.S. - Formulation strategies for absorption windows. - Drug Discov Today, 10, 249-257, 2005.
4. Kagan L., Hoffman A. - Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. - Expert Opin Drug Deliv., 5, 681-692, 2008. (Pubitemid 351998257)
5. Kararli T.T.- Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals.- Biopharm Drug Dispos., 16, 351-380, 1995.
6. Washington N., Washington C., Wilson C.G. - Physiological Pharmaceutics. Barriers to Drug Absorption. -Taylor and Francis Inc., New York, 2001.
7. Rouge N., Buri P., Doelker E. - Drug absorption sites in the gastrointestinal tract and dosage forms tor site-specific delivery. - Int J Pharm., 136, 117-139, 1996. (Pubitemid 26199405)
8. Wilding I. - Site-specific drug delivery in the gastrointestinal tract. - Crit Rev Ther Drug Carrier Syst., 17, 557-620, 2000. (Pubitemid 32064213)
9. Davis S.S., Wilding E.A., Wilding I.R. - Gastrointestinal transit of a matrix tablet formulation: comparison of canine and human data. - Int J Pharm., 94, 235-238, 1993.
10. Gusler G., Gorsline J., Levy G., Zhang S.Z., Weston I.E., Naret D., Berner B. - Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. - J Clin Pharmacol., 41, 655-661, 2001. (Pubitemid 32493360)
11. Ehrlein H.J. - Motility of the pyloric sphincter studied by the inductograph method in conscious dogs. -The American Journal of Physiology, 254, G650-657, 1988.
12. Hou S.Y., Cowles V.E., Berner B. - Gastric retentive dosage forms: a review. - Crit RevTher Drug Carrier Syst., 20,459-497, 2003. (Pubitemid 41646576)
13. Reddy L.H., Murthy R.S. - Floating dosage systems in drug delivery. - Crit Rev Ther Drug Carrier Syst., 19, 553-585, 2002.
14. Moes A. J. - Gastroretentive dosage forms. - Crit Rev Ther Drug Carrier Syst., 10, 143-195, 1993.
15. Streubel A., Siepmann J., Bodmeier R. - Gastroretentive drug delivery systems. - Exp Opin Drug Deliv., 3, 217-233, 2006.
16. Klausner E.A., Lavy E., Friedman M., Hoffman A. - Expandable gastroretentive dosage forms. - J Control Release, 90, 143-162, 2003.
17. Ozdemir N., Ordu S., Ozkan Y. - Studies of floating dosage forms of furosemide: In vitro and in vivo evaluations of bilayer tablet formulations. - Drug Dev Ind Pharm., 26, 857-866, 2000.
18. Whitehead L., Fell J.T., Collett J.H., Sharma H.L., Smith A. - Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. - J Control Release, 55, 3-12, 1998. (Pubitemid 28477559)
19. Klausner E.A., Lavy E., Stepensky D., Cserepes E., Barta M., Friedman M., Hoffman A. - Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. - J Clin Pharmacol., 43, 711-720, 2003. (Pubitemid 36759148)
20. Klausner E.A., Lavy E., Barta M., Cserepes E., Friedman M., Hoffman A. - Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. - Pharm Res., 20, 1466-1473, 2003. (Pubitemid 37164056)
21. Kagan L., Lapidot N., Afargan M., Kirmayer D., Moor E., Mardor Y., Friedman M., Hoffman A. - Gastroretentive accordion pill: enhancement of riboflavin bioavailability in humans. - J Control Release, 113, 208-215, 2006. (Pubitemid 43963188)
22. Gordi T, Hou E., Kasichayanula S., Berner B.- Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple- dose, three-way crossover, exploratory study in healthy subjects. - Clin Ther., 30, 909-916, 2008. (Pubitemid 351799872)
23. Chen J., Blevins W.E., Park H., Park K. - Gastric retention properties of superporous hydrogel composites. - J Control Release, 64, 39-51, 2000. (Pubitemid 30035306)
24. Fix J.A., Cargill R., Engle K. - Controlled gastric emptying. III. Gastric residence time of a nondisintegrating geometric shape in human volunteers. - Pharm Res., 10, 1087-1089, 1993.
25. Parikh D.C., Amin A.F. - In vitro and in vivo techniques to assess the performance of gastro-retentive drug delivery systems: a review. - Expert Opin Drug Deliv., 5, 951-965, 2008.
26. Klausner E.A., Eyal S., Lavy E., Friedman M., Hoffman A. - Novel levodopa gastroretentive dosage form: in vivo evaluation in dogs. - J Control Release, 88, 117-126, 2003. (Pubitemid 36173957)
27. Klausner E.A., Lavy E., Stepensky D., Friedman M., Hoffman A. - Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. - Pharm Res., 19, 1516-1523, 2002. (Pubitemid 35266557)
28. Kagan L., Hoffman A.- Selection of drug candidates for gastroretentive dosage forms: Pharmacokinetics following continuous intragastric mode of administration in a rat model.- Eur J Pharm Biopharm., 69, 238-246, 2008.
29. Kagan L., Lavy E., Hoffman A. - Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model. - Pulm Pharmacol Ther., 22, 260-265, 2009.
30. Cao X., Gibbs S.T., Fang I., Miller H.A., Landowski C.P., Shin H.C., Lennernas H., Zhong Y., Amidon G.L., Yu L.X., Sun D. - Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. - Pharm Res., 23, 1675-1686, 2006. (Pubitemid 44200529)
31. Zhao Y.H., Abraham M.H., Le J., Hersey A., Luscombe C.N., Beck G., Sherborne B., Cooper I. - Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. - Eur J Med Chem., 38, 233-243, 2003. (Pubitemid 36349666)
32. Chiou W.L., Barve A. - Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. - Pharm Res., 15, 1792-1795, 1998. (Pubitemid 28524594)
33. Fagerholm U., Johansson M., and Lennernas H. - Comparison between permeability coefficients in rat and human jejunum. - Pharm Res., 13, 1336-1342, 1996. (Pubitemid 26344978)
34. Ungell A.L., Nylander S., Bergstrand S., Sjoberg A., Lennernas H. - Membrane transport of drugs in different regions of the intestinal tract of the rat. - J Pharm Sei., 87, 360-366, 1998. (Pubitemid 28204591)
35. Bardonnet P.L., Faivre V., Pugh W.J., Piffaretti J.C., Falson F. - Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. - J Control Release, 111, 1-18, 2006. (Pubitemid 43289989)
36. Conway B.R. - Drug delivery strategies for the treatment of Helicobacter pylori infections. - Curr Pharm Des., 11, 775-790, 2005. (Pubitemid 40347980)
37. Rowland M., Tozer T.N. - Clinical Pharmacokinetics: Concepts and Application. - Lea & Febiger, New York, 1995.
38. Gabapentin. In: AHFS drug information, G.K. McEvoy Ed., American Society of Health System Pharmacists, Bethesda, 2008.
39. Neurontin package insert, US Food and Drug Administration, Center for Drug Evaluation and Research, http://www.fda.gov/ cder/foi/label/2005/20235s029, 20882s015,21129s016lbl.pdf (accessed January 15, 2009).
40. Stewart B.H., Kugler A.R., Thompson P.R., Bockbrader H.N. - A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. - Pharm Res., 10, 276-281, 1993.
41. Uchino H., Kanai Y., Kim D.K., Wempe M.F., Chairoungdua A., Morimoto E., Anders M.W., Endou H. -Transport of amino acid- related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. - MoI Pharmacol., 61, 729-737, 2002. (Pubitemid 34273151)
42. Cundy K.C., Annamalai T., Bu L., De Vera J., Estrela J., Luo W., Shirsat P., Torneros A., Yao F., Zou J., Barrett R.W., Gallop M.A.-XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. - J Pharmacol Exp Then, 311, 324-333, 2004. (Pubitemid 39287812)
43. Cundy K.C., Branch R., Chernov-Rogan T., Dias T., Estrada T., Hold K., Koller K., Liu X., Mann A., Panuwat M., Raillard S.P., Upadhyay S., Wu Q.Q., Xiang J.N., Yan H., Zerangue N., Zhou C.X., Barrett R.W., Gallop M.A. - XP13512 [(+/-)-1-([(alpha- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. - J Pharmacol Exp Ther., 311, 315-323, 2004.
44. Cundy K.C., Sastry S., Luo W., Zou J., Moors T.L., Canafax D.M. - Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. - J Clin Pharmacol., 48, 1378-1388, 2008.
45. Gabrielsson J., Weiner D. - Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. - Swedish Pharmaceutical Press, Stockholm, 2000.
46. McLean M.J. - Clinical pharmacokinetics of gabapentin. - Neurology, 44, S17-22; discussion S31-12, 1994.